Alternate Day Buprenorphine Administration, Phase XI - 16

This study has been completed.

Sponsors and Collaborators:	National Institute on Drug Abuse (NIDA) University of Vermont
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000234

Purpose

The purpose of this study is to evaluate open buprenorphine dosing with dose choice after open exposure.

Condition	Intervention	Phase
Opioid-Related Disorders	Drug: Buprenorphine	Phase II

Drug Information available for: Buprenorphine Buprenorphine hydrochloride

Study Type:	Interventional
Study Design:	Treatment, Placebo Control, Crossover Assignment
Official Title:	Alternate Day Buprenorphine Administration, Phase XI

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Estimated Enrollment:

Eligibility

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000234

Locations

United States, Vermont
Treatment Research Center
Burlington, Vermont, United States, 05401

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

University of Vermont

Investigators

Principal Investigator:

Warren Bickel, Ph.D.

University of Vermont

More Information

Study ID Numbers:	NIDA-06969-16, R01-06969-16
Study First Received:	September 20, 1999
Last Updated:	August 16, 2005
ClinicalTrials.gov Identifier:	NCT00000234
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Buprenorphine
Mental Disorders
Substance-Related Disorders
Disorders of Environmental Origin
Opioid-Related Disorders

Additional relevant MeSH terms:

Sensory System Agents
Therapeutic Uses
Narcotic Antagonists
Physiological Effects of Drugs
Central Nervous System Depressants
Narcotics

Peripheral Nervous System Agents
Analgesics
Central Nervous System Agents
Pharmacologic Actions
Analgesics, Opioid

ClinicalTrials.gov processed this record on January 15, 2009